Overview

Bioequivalence Study of Rivastigmine 1.5 mg Capsules Under Fasting Conditions

Status:
Completed

Trial end date:
2004-02-01

Target enrollment:

Participant gender:

Summary

This is a bioequivalence study of Rivastigmine 1.5 mg capsules and Exelon Administered as 1.5 mg capsule in Healthy subjects under fasting conditions.

Phase:

Phase 1

Details

Lead Sponsor:

Dr. Reddy's Laboratories Limited

Treatments:

Rivastigmine